Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Follow-up on AVAPERL Trial of Maintenance Alimta/Avastin vs. Avastin Alone
Author
Howard (Jack) West, MD

   A few months ago I wrote about the preliminary reported results from the AVAPERL trial, which started patients with previously untreated  advanced nonsquamous NSCLC up to four cycles of cisplatin/Alimta (pemetrexed)/Avastin (bevacizumab), then randomized patients who hadn't progressed after four cycles to either maintenance Alimta/Avastin or Avastin alone.  At the Eurpean Society for Medical Oncology (ESMO) 2011 meeting, the investigators (Barlesi and colleagues) presented early results that showed a very significant improvement in progression-free survival (PFS) from the beginning of all treatment, at 10.2 vs. 6.6 months (HR 0.50, p < 0.001).  For those of you who understand things better visually, here's the curve plotting the PFS outcome for the two different groups, with a very impressive difference: avaperl-pfs 

 

 

 

 

 

 

 

 

  (click on image to enlarge)

   The same results, plotted from the time of randomization to combination vs. single agent Avastin as maintenance therapy, are even more striking:

avaperl-pfs-from-maintenance  

   I didn't have any information about overall survival (OS) back in September, but here's the preliminary OS results, with numbers from the time of starting all treatment:

 

 

 

 

 

 

avaperl-os

 

So while these are only preliminary results, the difference of a 25% better OS with continuation of Alimta is impressive to me, especially considering that the arm with the worse outcome, receiving maintenance Avastin alone, has a median survival of nearly 16 months, which we would consider to be quite excellent compared the outcome of other advanced NSCLC trials (12 months for cisplatin/Alimta on one large phase III randomized trial, 12 months with carboplatin/Taxol (paclitaxel) with Avastin in another).  So the inferior arm on AVAPERL has still done very well: the superior arm is just doing meaningfully better.

   My take home messages from this work, though it's from just one trial without a huge number of patients, is that:

1) Maintenance Avastin on its own may or may not add anything, but adding another agent with good activity against NSCLC (at least Alimta) is likely better; it's unclear whether the Avastin is adding anything to the combination.  That'll be tested directly in the ECOG 5508 trial that is ongoing now.

2) Clearly the value of the Alimta hasn't been exhausted by continuing it after four cycles of initial therapy in the first line setting.  In patients who aren't progressing and are tolerating it well, more is better.

   I'll discuss some other evidence along these lines in my next post.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on